CAPR catalyst calendar

CAPRICOR THERAPEUTICS, INC.

Upcoming catalysts
1
Cash runway
10.3 months
Cash & investments
$100M
Phase 3 programs
1

CAPRICOR THERAPEUTICS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 12, 2026, a projected date rather than a confirmed one. There is 1 upcoming event on record.

Cash runway is approximately 10.3 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Across 7 concluded trials, 86% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 12, 2026 est. Next quarterly earnings (projected) Earnings —

Track CAPR alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open CAPR in the tracker

Recent history

DateEventTypePhase
August 24, 2026 8-K filed: Other event Filing —
August 13, 2026 Quarterly results filed (8-K) Earnings —
July 30, 2026 8-K filed: Other event Filing —
July 29, 2026 8-K filed: Other event Filing —
July 14, 2026 8-K filed: Material agreement Corporate —
June 26, 2026 8-K filed: Other event Filing —
May 12, 2026 Quarterly results filed (8-K) Earnings —
May 7, 2026 8-K filed: Reg FD disclosure, Other event Filing —
March 12, 2026 Quarterly results filed (8-K) Earnings —
March 10, 2026 8-K filed: Reg FD disclosure, Other event Filing —
December 5, 2025 8-K filed: Reg FD disclosure, Other event Filing —
December 3, 2025 8-K filed: Reg FD disclosure, Other event Filing —
December 3, 2025 8-K filed: Reg FD disclosure Filing —
November 10, 2025 Quarterly results filed (8-K) Earnings —
August 11, 2025 Quarterly results filed (8-K) Earnings —
July 11, 2025 8-K filed: Reg FD disclosure Filing —
June 18, 2025 A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy Trial Milestone Phase 3
May 27, 2025 8-K filed: Leadership change Corporate —
May 13, 2025 Quarterly results filed (8-K) Earnings —
February 16, 2022 Open-label Extension of the HOPE-2 Trial Trial Milestone Phase 2
February 4, 2022 Intravenous Infusion of CAP-1002 in Patients With COVID-19 Trial Milestone Phase 2
March 10, 2020 A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy Trial Milestone Phase 2
March 6, 2019 Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE) Trial Milestone Phase 2
September 14, 2017 HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) Trial Milestone Phase 2
July 3, 2017 Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration Trial Milestone Phase 1/Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.